Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 8/20 | 0.42 |
| ▸ | MASP2 | O00187 | 7/20 | 0.42 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.39 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.39 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7721710 | 1.00 | ALOX15 (0.45) | ALOX15MAPK1F2MASP2PADI4 | |
| SCHEMBL21436585 | 1.00 | ALOX15 (0.45) | ALOX15MAPK1F2MASP2PADI4 | |
| SCHEMBL7733115 | 1.00 | ALOX15 (0.45) | ALOX15MAPK1F2MASP2PADI4 | |
| SCHEMBL21436279 | 0.90 | F2 (0.38) | F2MASP2PADI4PADI2KLKB1 | |
| SCHEMBL21436256 | 0.90 | F2 (0.42) | F2MASP2PADI4PADI2KCNMA1 | |
| SCHEMBL7731163 | 0.90 | F2 (0.42) | F2MASP2PADI4PADI2KCNMA1 | |
| SCHEMBL7729695 | 0.90 | F2 (0.38) | F2MASP2PADI4PADI2KLKB1 | |
| SCHEMBL7728852 | 0.90 | F2 (0.38) | F2MASP2PADI4PADI2KLKB1 | |
| SCHEMBL7733729 | 0.90 | F2 (0.42) | F2MASP2PADI4PADI2KCNMA1 | |
| SCHEMBL7723535 | 0.87 | ALOX15 (0.44) | ALOX15MAPK1F2MASP2PADI4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11419834-B2 | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide | RHODE ISLAND HOSPITAL (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210137948-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2021-05-13 | — | — | US | disclosed |
| EP-3773602-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2021-02-17 | — | — | EP | disclosed |
| US-20200268693-A1 | METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE | RHODE ISLAND HOSPITAL | 2020-08-27 | — | — | US | disclosed |
| US-20190328687-A1 | Antibacterial Compounds | VICTORIA LINK LIMITED (NZ) | 2019-10-31 | — | — | US | disclosed |
| WO-2019192968-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | UNION therapeutics A/S (DK) | 2019-10-10 | — | — | WO | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200268693-A1 | METHODS FOR TREATING DISEASES OR INFECTIONS CAUSED BY OR ASSOCIATED WITH H. PYLORI USING A HALOGENATED SALICYLANILIDE | MALT1, SI, BCL6 | ALOX15 215/4885MAPK1 3925/4885F2 4166/4885 |
| US-11419834-B2 | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide | MALT1, SI, BCL6 | ALOX15 215/4885MAPK1 3925/4885F2 4166/4885 |
| US-20210137948-A1 | TREATMENT OF INFECTIONS CAUSED BY NEISSERIA GONOCOCCUS USING A HALOGENATED SALICYLANILIDE | MGLL, NIT2, SI | ALOX15 1068/4885MAPK1 3049/4885F2 2844/4885 |
| US-20190328687-A1 | Antibacterial Compounds | SHARPIN, FDPS, BROX | ALOX15 576/4885MAPK1 2319/4885F2 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.